Arena Investment Management (Singapore) Pte Ltd - Net Worth and Insider Trading

Arena Investment Management (Singapore) Pte Ltd Net Worth

The estimated net worth of Arena Investment Management (Singapore) Pte Ltd is at least $54 Million dollars as of 2024-11-13. Arena Investment Management (Singapore) Pte Ltd is the 2102 Investment manager of Huakang Biomedical Holdings Co Ltd and owns about 259,424,000 shares of Huakang Biomedical Holdings Co Ltd (HKSE:08622) stock worth over $54 Million. Details can be seen in Arena Investment Management (Singapore) Pte Ltd's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Arena Investment Management (Singapore) Pte Ltd has not made any transactions after 2024-05-07 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Arena Investment Management (Singapore) Pte Ltd

Arena Investment Management (Singapore) Pte Ltd Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Arena Investment Management (Singapore) Pte Ltd owns 1 companies in total, including Huakang Biomedical Holdings Co Ltd (HKSE:08622) .

Click here to see the complete history of Arena Investment Management (Singapore) Pte Ltd’s form 4 insider trades.

Insider Ownership Summary of Arena Investment Management (Singapore) Pte Ltd

Ticker	Comapny	Transaction Date	Type of Owner
HKSE:08622	Huakang Biomedical Holdings Co Ltd	2024-06-03	2102 Investment manager

Arena Investment Management (Singapore) Pte Ltd Latest Holdings Summary

Arena Investment Management (Singapore) Pte Ltd currently owns a total of 1 stock. Arena Investment Management (Singapore) Pte Ltd owns 259,424,000 shares of Huakang Biomedical Holdings Co Ltd (HKSE:08622) as of May 7, 2024, with a value of $54 Million.

Latest Holdings of Arena Investment Management (Singapore) Pte Ltd

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
HKSE:08622	Huakang Biomedical Holdings Co Ltd	2024-05-07	259,424,000	0.21	53,960,192

Holding Weightings of Arena Investment Management (Singapore) Pte Ltd

Arena Investment Management (Singapore) Pte Ltd Form 4 Trading Tracker

According to the SEC Form 4 filings, Arena Investment Management (Singapore) Pte Ltd has made a total of 1 transactions in Huakang Biomedical Holdings Co Ltd (HKSE:08622) over the past 5 years, including 0 buys and 0 sells. The most-recent trade in Huakang Biomedical Holdings Co Ltd is the sale of 138,672,000 shares on May 7, 2024, which brought Arena Investment Management (Singapore) Pte Ltd around $0.

Insider Trading History of Arena Investment Management (Singapore) Pte Ltd

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Arena Investment Management (Singapore) Pte Ltd Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Arena Investment Management (Singapore) Pte Ltd Ownership Network

Ownership Network List of Arena Investment Management (Singapore) Pte Ltd

No Data

Ownership Network Relation of Arena Investment Management (Singapore) Pte Ltd

Arena Investment Management (Singapore) Pte Ltd Owned Company Details

What does Huakang Biomedical Holdings Co Ltd do?

Who are the key executives at Huakang Biomedical Holdings Co Ltd?

Arena Investment Management (Singapore) Pte Ltd is the 2102 Investment manager of Huakang Biomedical Holdings Co Ltd. Other key executives at Huakang Biomedical Holdings Co Ltd include 2102 Investment manager Arena Investors, LP , 2201 Interest of corporation controlled by you Arena SG SPV I, LLC , and 2106 Person having a security interest in shares TGGA, LLC .

Huakang Biomedical Holdings Co Ltd (HKSE:08622) Insider Trades Summary

Over the past 18 months, Arena Investment Management (Singapore) Pte Ltd made 1 insider transaction in Huakang Biomedical Holdings Co Ltd (HKSE:08622) with a net sale of 0. Other recent insider transactions involving Huakang Biomedical Holdings Co Ltd (HKSE:08622) include a net purchase of 100,496,000 shares made by Lau LAI YEE , a net purchase of 108,024,000 shares made by Kokusai Resources Company Limited , and a net sale of 34,160,000 shares made by Zhang Shuguang .

In summary, during the past 3 months, insiders sold 0 shares of Huakang Biomedical Holdings Co Ltd (HKSE:08622) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 102,480,000 shares of Huakang Biomedical Holdings Co Ltd (HKSE:08622) were sold and 208,520,000 shares were bought by its insiders, resulting in a net purchase of 106,040,000 shares.

Huakang Biomedical Holdings Co Ltd (HKSE:08622)'s detailed insider trading history can be found in Insider Trading Tracker table.

Huakang Biomedical Holdings Co Ltd Insider Transactions

No Available Data

Arena Investment Management (Singapore) Pte Ltd Mailing Address

Above is the net worth, insider trading, and ownership report for Arena Investment Management (Singapore) Pte Ltd. Currently GuruFocus does not have mailing address information for Arena Investment Management (Singapore) Pte Ltd.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.